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Renal excretion of organic anions such as
para-aminohippurate is reduced during severe sepsis and
following ischemia/reperfusion injury. In order to better
define the pathophysiology of sepsis-associated renal tubular
dysfunction we measured the effect of lipopolysaccharide on
renocortical organic anion transporter (OAT) expression in
the rat. Prostaglandin E2 (PGE2) downregulates OATs in vitro,
therefore, we also evaluated the effect of the cyclooxygenase
(COX)-2 inhibitor parecoxib on this process. Endotoxemia
caused a time- and dose-dependent decrease of OAT1 and
OAT3 expression that paralleled increased renocortical COX-2
expression and PGE2 formation. Pretreatment with parecoxib
decreased endotoxin-stimulated PGE2 formation. Parecoxib
attenuated OAT1 and OAT3 gene repression in the rat kidney
following endotoxin treatment and during ischemia/
reperfusion-induced acute renal injury. COX-2 inhibition
improved the creatinine clearance in lipopolysaccharide-
treated rats but not after ischemia/reperfusion-induced acute
renal injury. The decreased clearance of para-aminohippurate
in rats following endotoxin- or ischemia/reperfusion-induced
renal injury was improved by parecoxib. Our findings show
that COX-2 derived prostanoids downregulate OATs during
lipopolysaccharide-induced acute renal injury.
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Sepsis and septic shock are important risk factors for acute
renal failure (ARF), which is defined as the abrupt decline in
glomerular filtration rate and tubular function.1 The
mortality rate of sepsis-related ARF is still high at 75%.2
Therefore, the understanding of the pathogenesis of sepsis-
related ARF is of critical importance. Several in vivo and in
vitro studies have suggested that the reduction of glomerular
filtration rate in sepsis is secondary to altered glomerular
hemodynamics.3 However, the pathophysiology of sepsis-
associated renal tubular dysfunction with altered renal
handling of drugs has been poorly explained.
The kidney excretes a large variety of drugs. Two principle
processes are responsible for their renal elimination:
glomerular filtration and proximal tubular secretion.4 The
tubular secretion of organic anions, for example, needs
cellular transport mechanisms. Organic anion transporters
(OATs) are necessary for the uptake of organic anions from
the peritubular plasma across the basolateral membrane into
the proximal tubule cell in exchange for a-ketoglutarate.5
Among the several OATs, the transporters OAT1 and OAT3
have been proposed to be responsible for this step.6 In the
past years, it became apparent that several chemically
unrelated endogenous and exogenous compounds, like
para-aminohippurate (PAH), cAMP, diuretics, and antibio-
tics are transported such as the OAT system.6 In addition,
prostaglandin E2 (PGE2) is secreted into the urine at
substantial rates by the OAT system of renal proximal
tubules, likely by OAT1 and OAT3.6,7 Recently, it has been
demonstrated that PGE2 downregulates the expression OAT1
and OAT3 in vitro.8 Moreover, it has been found that OATs
are downregulated during ischemia/reperfusion (I/R)-in-
duced ARF and ureteral obstruction,9–11 conditions under
which renal cyclooxygensase (COX)-2 expression is in-
creased.12,13 Therefore, one may assume that the down-
regulation of OATs during ARF could be because of an
increased formation of COX-2 derived PGE2.
As renal COX-2 expression is increased in response to
lipopolysaccharide (LPS),14 which is an experimental
approach commonly used in examining the pathogenesis of
sepsis, and because administration of LPS alters the renal
handling of several drugs,15–22 we investigated in this study
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the effect of LPS on the expression of OAT1 and OAT3 in the
rat renal cortex. As we found that the LPS-induced down-
regulation of OATs is paralleled by an increased expression of
renocortical COX-2 gene, we hypothesized that the down-
regulation of OATs during endotoxemia could be because of
an enhanced formation of COX-2 derived PGE2 in the rat
renal cortex. Therefore, we studied the effect of the COX-2
inhibitor parecoxib on LPS-induced downregulation of
renocortical OATs and in addition on I/R-induced down-
regulation of OATs.
RESULTS
Effect of LPS on OAT1 and OAT3 expression
Injection of LPS for 3 h did not alter mRNA expression of
OAT1 and OAT3. However, treatment with LPS for 6 and
12 h decreased OAT1 and OAT3 mRNA expression in the rat
renal cortex. OAT1 mRNA was downregulated to 56 and 42%
of control levels 6 and 12 h after LPS injection, respectively.
OAT3 mRNA levels decreased to 44 and 30% of control levels
6 and 12 h after LPS administration, respectively (Figure 1a).
Injection of increasing doses of LPS (1, 3, and 10 mg/kg)
caused a dose-dependent downregulation of OAT1 mRNA
abundance to 67, 50, and 44% of control levels 12 h after LPS
injection, respectively. OAT3 mRNA abundance also de-
creased dose dependent to 55, 40, and 29% of control values,
respectively (Figure 1b). We further investigated the expres-
sion of OAT1 and OAT3 protein in basolateral membranes
from the renal cortex of vehicle and LPS-treated animals and
found that the expression of OAT1 and OAT3 protein was
decreased in animals treated for 12 h with LPS (Figure 1c).
OAT1 immunoreactivity was detected in proximal tubules of
vehicle-treated rats and was clearly decreased in rats treated
with LPS (Figure 2a–d).
Time- and dose-dependent effect of LPS on COX-1 and COX-2
expression and on renocortical PGE2 formation
We further evaluated the effect of LPS on renocortical PGE2
formation and on the expression of the two COX-isoforms,
because it has been suggested that PGE2 downregulates OATs
in vitro.8 Intravenous injection of LPS did not influence renocor-
tical COX-1 gene expression (Figure 3a–c). Treatment with LPS
(10 mg/kg) for 3, 6, and 12 h increased COX-2 mRNA expression
in the rat renal cortex 3.1-, 3.8-, and 3.4-fold, respectively (Figure
3a). Injection of increasing doses of LPS (1, 3, and 10 mg/kg)
caused a dose-dependent upregulation of COX-2 mRNA
abundance to 190, 249, and 379% of control levels 12 h after
LPS injection, respectively (Figure 3b). Twelve hours after LPS
injection, renocortical COX-2 protein expression was increased
about twofold of control levels (Figure 3c). The increase in COX-2
gene expression was paralleled by an increase in renocortical
PGE2 concentration to 188% of baseline values (Figure 3d).
Effect of parecoxib on LPS-induced renocortical PGE2
concentration
To evaluate the role of COX-2 derived PGE2 for the
downregulation of OATs during LPS treatment, we further
investigated the effect of the COX-2 inhibitor parecoxib
(20 mg/kg; i.p.). Parecoxib treatment decreased basal PGE2
tissue concentration to about 76% of control values and
pretreatment with parecoxib for 1 h inhibited the LPS-
induced rise in renocortical PGE2 formation (Figure 3d).
Effect of parecoxib on LPS-induced downregulation of OAT1
and OAT3 expression
Sole parecoxib treatment did not influence the expression of
OAT1 and OAT3 (Figure 4a–d). In animals treated for 12 h
with LPS in combination with parecoxib, mRNA expression
of OAT1 substantially increased from 33 to 70% compared to
treatment with LPS alone (Figure 4a). Furthermore, the
150
100
50
0
150
100
50
0
150
100
50
0
Vehicle 
LPS
Control
LPS 1 mg/kg
LPS 3 mg/kg
LPS 10 mg/kg
Time (h)
O
AT
/β-
a
ct
in
 m
R
N
A
(%
 of
 co
ntr
ol)
O
AT
/β-
a
ct
in
 m
R
N
A
(%
 of
 co
ntr
ol)
ir-
O
AT
 p
ro
te
in
(%
 of
 co
ntr
ol)
0 3 6 9 12
OAT 1
OAT 3
OAT 1 OAT 3
OAT 1 OAT 3
Figure 1 | Effect of lipopolysacharide (LPS) on organic anion
transporters (OATs). (a) Time-dependent effect of LPS (10 mg/
kg) on renocortical OAT1 and OAT3 mRNA expression related to
b-actin mRNA expression. (b) Dose-dependent effect of LPS on
renocortical OAT1 and OAT3 mRNA expression related to b-actin
mRNA expression. (c) Effect of LPS (10 mg/kg for 12 h) on OAT1
and OAT3 protein expression in basolateral membranes from the
renal cortex. Insets show representative immunoblots for OAT1
and OAT3. Values are mean±s.e.m. for six rats. *Po0.05 vs
control.
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combination of LPS with parecoxib attenuated the LPS-
induced downregulation of OAT3 mRNA abundance from 43
to 70% (Figure 4b). Consistent with the mRNA expression
levels, the decreased immunoreactivity of OAT1 and OAT3 in
LPS-treated rats was markedly attenuated in response to
additional parecoxib treatment (Figure 4c and d).
Renal and hemodynamic parameters of rats
Mean arterial pressure (MAP) decreased 12 h after LPS
injection from 92±4 to 47±7 mm Hg. Sole parecoxib did
not alter MAP, but attenuated the LPS-induced fall in MAP
to about 72±6 mm Hg. Plasma urea levels and plasma
creatinine levels increased 3.4- and 2.8-fold after injection of
LPS, respectively. Parecoxib did not alter plasma creatinine
levels, but attenuated the LPS-induced rise in plasma
creatinine levels (Figure 5a). LPS injection decreased
creatinine clearance from 0.85±0.07 to 0.36±0.04 ml/min.
Parecoxib did not alter creatinine clearance, but attenuated
the LPS-induced decrease in creatinine clearance (Figure 5b).
PAH clearance was decreased 12 h after LPS injection.
Parecoxib did not alter PAH clearance, but attenuated the
Control LPS
Figure 2 | Immunohistochemistry of OAT1 in the renal cortex.
Vehicle (a, c) and LPS-treated rats (b, d). These figures are
representative of typical samples from three rats. a, b 200.
c, d 400.
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Figure 3 | Time- and dose-dependent effects of lipopolysacharide (LPS) on cyclooxygenase (COX) gene expression and effect of
parecoxib on renocortical prostaglandin (PG) E2 concentration. (a) Time- (LPS 10 mg/kg for 0, 3, 6, and 12 h) and (b) dose-dependent
effect of LPS (1, 3, and 10 mg/kg for 12 h) on renocortical COX-1 and COX-2 mRNA expression related to b-actin mRNA expression. (c)
Renocortical COX-1 and COX-2 protein expression in rats treated with LPS (10 mg/kg) for 12 h. (d) Renocortical prostaglandin E2 (PGE2)
concentration in rats treated with LPS (10 mg/kg), parecoxib (20 mg/kg) or the combination of LPS with parecoxib for 12 h. Inset shows
representative immunoblots for COX-1 and COX-2. Values are mean±s.e.m. for six rats. *Po0.05 vs control. #Po0.05 vs LPS.
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LPS-induced fall in PAH clearance (Figure 5c). We further
calculated tubular PAH secretion, which was not altered by
sole treatment with parecoxib. However, parecoxib attenu-
ated the LPS-induced fall in PAH net secretion (Figure 5d).
Effect of parecoxib on I/R-induced downregulation of OAT1
and OAT3 expression and on renal parameters
MAP was not altered by I/R nor by additional or sole
treatment with parecoxib after 12 h compared to the sham
group. Ischemia for 30 min and reperfusion for 12 h
decreased renocortical OAT1 and OAT3 expression. Sole
parecoxib treatment did not influence the expression of
OAT1 and OAT3 (Figure 6a–c), but attenuated the I/R-
induced downregulation of OATs. The expression of OAT1
increased from 35 to 65% and the expression of OAT3 from
22 to 47% (Figure 6a–c). I/R clearly increased renocortical
COX-2 protein expression as well as renocortical PGE2 tissue
concentration (Figure 6d). Parecoxib did not influence
plasma creatinine levels and did not alter the I/R-induced
rise in plasma creatinine levels (Figure 7a). Parecoxib did not
influence basal creatinine clearance and did not alter the I/R-
induced decrease in creatinine clearance (Figure 7b).
Parecoxib did not influence basal PAH clearance, but
attenuated the I/R-induced fall in PAH clearance (Figure
7c). Parecoxib did not change basal tubular PAH secretion,
but attenuated the I/R-induced fall in tubular PAH secretion
(Figure 7d).
DISCUSSION
In this study, we aimed to characterize the regulation of
renocortical OATs during severe experimental inflammation. A
bolus of 10 mg/kg LPS in our in vivo model caused a
pronounced arterial hypotension associated with increased
plasma creatinine levels, reduced creatinine clearance and
reduced PAH clearance, indicating the validity of our model
of severe experimental sepsis.23,24 In line with a previous
observation, we found that injection of LPS does not alter
renocortical COX-1 expression, but that LPS increases renocor-
tical COX-2 mRNA and protein expression,14 suggesting that
the increase of COX-2 in the renal cortex is a rapid process that
is because of enhanced de novo synthesis of COX-2 protein
rather than to impaired degradation. We further found that the
increase in COX-2 is dose dependent and that the increase in
renocortical COX-2 expression leads to an enhanced formation
of renocortical PGE2. This finding fits with previous studies
reporting a dose-dependent increase in renal tissue cytokine
formation,25–27 which are well-known stimuli for COX-2
expression during inflammation.28
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We now found that LPS-induced ARF caused a time- and
dose-dependent downregulation of OAT1 and OAT3 gene
expression. Recently, it has been reported that PGE2 regulates
OAT gene expression in vitro. It has been shown that PGE2
inhibits its own renal transport by downregulation of OAT1
and OAT3 gene expression in vitro.8 In addition, it has been
found that I/R downregulates the renal expression of OAT1
and OAT3.9,10 As COX-2 expression is increased under
endotoxemia and I/R,12 one might suggest that the down-
regulation of OATs during ARF could be because of an
enhanced formation of COX-2 derived PGE2. We attempted
to prove such a causal link between COX-2 expression and
OAT1 and OAT3 expression by the use of the COX-2
inhibitor parecoxib. Parecoxib clearly attenuated the LPS-
induced increase in renocortical PGE2 tissue concentration,
suggesting that the LPS-induced rise in PGE2 concentration is
COX-2 dependent. We now found that COX-2 inhibition
attenuates the LPS-induced downregulation of OAT1 and
OAT3 gene expression, suggesting that COX-2 derived PGE2
formation is of importance for the LPS-induced down-
regulation of OATs.
To prove the functional consequence for the attenuated
downregulation of OAT1 and OAT3 gene expression, we
further investigated the renal clearance of PAH. Within the
kidney, the organic anion PAH undergoes glomerular
filtration and tubular secretion.29 With regard to the
basolateral uptake of PAH from the blood into proximal
tubule cells, especially OAT1 and OAT3 are of major
importance and therefore for the tubular secretion of
PAH.29 Confirming previous observations, COX-2 inhibition
per se did not alter plasma creatinine concentration,
creatinine clearance, and PAH clearance.30,31 In line with
data obtained for indomethacin, a nonselective COX
inhibitor, we found that the LPS-induced decrease in PAH
clearance was ameliorated by COX-2 inhibition, suggesting
that the uptake of PAH and therefore the secretion of PAH is
improved.17 However, inhibition of COX-2 also ameliorated
the LPS-induced fall in creatinine clearance, probably because
of the attenuation of LPS-induced hypotension.24 As the
clearance of PAH depends on glomerular filtration rate and
tubular secretion, the amelioration of PAH clearance by
COX-2 inhibition could be because of the attenuation of OAT
gene expression or because of the amelioration of glomerular
filtration rate.
To further specify the impact of COX-2 derived prosta-
noids for the downregulation of OATs and for the renal
excretion of PAH, we further studied the effect of parecoxib
on OAT gene expression and PAH clearance under I/R. In line
with previous reports, we found that I/R downregulates
OAT1 and OAT3 gene expression and that this down-
regulation is paralleled by a decrease in PAH clearance.9,10 We
now found that COX-2 inhibition attenuates the down-
regulation of OAT1 and OAT3 gene expression in response to
ischemia, suggesting that COX-2 derived prostanoids are of
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importance for this downregulation under I/R. To prove this
assumption, we investigated the effect of I/R on renocortical
COX-2 protein expression and on renocortical PGE2
concentration and found that COX-2 protein as well as
PGE2 tissue concentration were increased under I/R. This
finding fits very well with other studies reporting of an
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increased COX-2 expression under I/R.12,32–34 In line with a
previous report, COX-2 inhibition did not ameliorate
creatinine clearance in response to I/R in our study.31 We
also found that MAP was not altered after I/R.35 The
unchanged MAP under I/R may be therefore a good
explanation, why additional parecoxib treatment did not
alter the decrease in creatinine clearance under I/R. However,
the COX-2 inhibitor parecoxib attenuated the decrease in
PAH clearance. As parecoxib did not alter creatinine
clearance during I/R, the amelioration of PAH clearance by
parecoxib under I/R could be because of the attenuation of
the downregulation of OAT gene expression.
COX-2 inhibition did not completely abolish the down-
regulation of OATs during LPS-induced and I/R-induced
ARF. Therefore, additional mechanisms have to be involved
into the downregulation of OATs. As cAMP has been shown
to increase the expression of at least human OAT3 gene and
because adenylyl cyclases expression and therefore cAMP
synthesis is decreased in response to LPS and I/R,36–38 a
decreased synthesis of cAMP might be a possible additional
mechanism that could be responsible for the downregulation
of renal OATs.
In conclusion, we found that LPS-induced renocortical
COX-2 gene expression and PGE2 formation is paralleled by a
downregulation of OAT1 and OAT3 gene expression. Inhibition
of COX-2 attenuated the LPS-induced decrease in OAT1 and
OAT3 gene expression. Further, COX-2 inhibition attenuated
the downregulation of renocortical OAT1 and OAT3 expression
because of I/R. Moreover, COX-2 inhibition ameliorated LPS-
induced renal dysfunction and attenuated LPS and ischemia-
induced decrease of PAH transport. Therefore, this study
contributes to our understanding about the mechanism of
regulation and the pathophysiological implications of OATs
under ARF. However, because COX-2 inhibition does not
completely attenuate the downregulation of OATs during LPS-
induced and I/R-induced ARF, additional mechanisms must be
involved in the downregulation of renal OATs.
MATERIALS AND METHODS
Experimental animals
All animal experiments were performed according to National
Institutes of Health Guide for the Care and Use of Laboratory Animals.
Male Sprague–Dawley rats (200–225 g) were obtained from Charles
River (Sulzfeld, Germany). Rats received isotonic NaCl-solution
(control) or LPS (Escherichia coli; Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany; 10 mg/kg) intravenously and were killed 3, 6,
or 12 h (n¼ 6 per group) after LPS injection. In addition, rats (n¼ 6
per group) treated with parecoxib (20 mg/kg; i.p.) alone or
parecoxib 1 h before LPS injection were investigated. The doses of
LPS and of parecoxib were chosen from the literature.31,39 Rats were
anesthetized with sevoflurane, using a Trajan 808 (Dra¨ger, Lu¨beck,
Germany). For induction of renal I/R injury, renal arteries of rats
(n¼ 6 per group) were totally occluded for 30 min with micro-
aneurysm clamps followed by reperfusion for 12 h. In sham controls,
renal arteries were only touched with a forceps. The right femoral
artery was cannulated for continuous monitoring of MAP (Siemens
SC 9000, Munich, Germany). The left femoral vein was cannulated
for maintenance infusion and the bladder for collecting urine.
Clearance of PAH, plasma levels of creatinine, and creatinine
clearance were determined as described previously.40,41
Real-time PCR analysis
Real-time PCR was performed in a LightCycler (Roche, Mannheim,
Germany) as described previously.42 The primer sets were chosen
from the literature.10 For each sample, the ratio of the amount of
mRNA to b-actin mRNA was calculated.
Protein preparation and Western blot
Protein preparation and immunoblotting were performed as
described previously.43 Antibodies against OAT1 and OAT3 (Alpha
Diagnostics, San Antonio, TX, USA; 1:500) and COX-1 and COX-2
(Cayman Chemical, Ann Arbor, MI, USA; 1:1,000) were used. The
preparation of basolateral membranes was performed as described
in the literature by others.11 OAT1 and OAT3 were detected as
approximately 60- and 110-kDa bands, respectively, as previously
reported.10,44–46
Immunohistochemistry
The kidneys were perfusion fixed with 4% paraformaldehyde and
processed as described.47 Immunolabeling was performed on 5-mm
paraffin sections. Sections were incubated with a commercial
available antibody against OAT1 (Alpha Diagnostics; 1:200) over-
night at 4 1C. After several washing steps and blocking with
phenylhydrazine, the sections were incubated with a rhodamine
(tetramethyl rhodamine isothiocyanate)-conjugated fluorescent
antibody (Dianova, Hamburg, Germany) for 2 h and mounted with
glycergel (DakoCytomation, Glostrup, Denmark).
Determination of tissue PGE2 levels
Renocortical tissue levels of PGE2 were assayed as described
previously.48
Statistical analyses
Data were analyzed by analysis of variance with multiple
comparisons followed by the t-test with Bonferroni adjustment.
Po0.05 was considered significant.
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